RPRXHealthcare · BiotechnologyThe 8 Wall Street analysts covering Royalty Pharma plc hold a median 12-month price target of $66 — +17.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 87 of 100 as at 8 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Royalty Pharma plc on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (100): The share price has been relatively steady.
Issuance (33): The company has been issuing shares or taking on financing, diluting existing holders.
Size (7): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on RPRX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +17.4% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Oct 2026 | Morgan Stanley | Maintains | Overweight | $65 → $67 |
| 8 Sept 2026 | TD Cowen | Maintains | Buy | $65 → $68 |
| 7 Aug 2026 | JP Morgan | Maintains | Overweight | $58 → $62 |
| 7 Aug 2026 | JP Morgan | Maintains | Overweight | — |
| 13 July 2026 | TD Cowen | Maintains | Buy | $50 → $65 |
| 13 July 2026 | TD Cowen | Maintains | Buy | — |
| 7 May 2026 | Citigroup | Maintains | Buy | — |
| 7 May 2026 | JP Morgan | Maintains | Overweight | — |
| 21 Apr 2026 | UBS | Maintains | Buy | — |
| 10 Apr 2026 | Morgan Stanley | Maintains | Overweight | — |
| 30 Jan 2026 | UBS | Upgrade | Buy | — |
| 27 Jan 2026 | Citigroup | Maintains | Buy | — |
| 11 Dec 2025 | TD Cowen | Maintains | Buy | — |
| 10 Oct 2025 | Morgan Stanley | Maintains | Overweight | — |
| 30 Sept 2025 | Goldman Sachs | Initiates | Buy | — |
| 22 July 2025 | Citigroup | Maintains | Buy | — |
| 10 July 2025 | Morgan Stanley | Maintains | Overweight | — |
| 25 Oct 2024 | Citigroup | Maintains | Buy | — |
| 14 Aug 2024 | Goldman Sachs | Maintains | Buy | — |
| 11 July 2024 | Morgan Stanley | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RPRX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Royalty Pharma plc returned +59.2% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 26% of US stocks
Cheaper than 12% of US stocks
Cheaper than 27% of US stocks
Cheaper than 12% of US stocks
Higher than 65% of US stocks
Higher than 12% of US stocks
Higher than 79% of US stocks
Higher than 91% of US stocks
Higher than 72% of US stocks
Higher than 77% of US stocks
Higher than 76% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Royalty Pharma plc has a market value of $32.5B and an enterprise value of $36.4B.
Revenue in the twelve months to 30 June 2026: $2.5B. The latest quarter grew 16.5% year on year.
Net income over the same four quarters: $1.3B, a 53.2% net margin.
Diluted earnings per share, trailing twelve months: $1.46.
Free cash flow in the twelve months to 30 June 2026: $3.0B.
Royalty Pharma plc spent $321.8M on share buybacks and $399.1M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 29.9×; forward P/E: 9.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 1.67%, paying out 48% of earnings.
Royalty Pharma plc employs 100 people — $25.4M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Royalty Pharma plc — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research says Royalty Pharma has an impressive history of earnings surprises and currently has two key ingredients associated with a likely beat in its next quarterly report.
Why it matters — The item highlights factors that could support a quarterly earnings surprise, which may interest RPRX watchers following the upcoming report.
The Motley Fool highlights that Royalty Pharma holds stakes in a diversified portfolio of 16 blockbuster drug products and candidates, describing the company's approach as an optimal way to gain exposure to solid returns with minimal downside risk.
Why it matters — RPRX watchers would care because the article underscores the company's diversified royalty portfolio and its positioning as a lower-risk way to access pharmaceutical returns.
Royalty Pharma executives said the company is monitoring a shifting biopharma policy environment, expanding its artificial-intelligence capabilities, and building a presence in China, while maintaining a disciplined approach to capital deployment and leverage.
Why it matters — A RPRX watcher would care because these developments signal strategic priorities that could shape the company's future growth and capital management.
Revolution Medicines received encouraging news around a drug aimed at treating pancreatic cancer. However, the article notes that despite having multiple drugs in development, investing in Revolution Medicines remains a concentrated, single-basket bet, and explores whether Royalty Pharma stock offers a safer way to gain exposure.
Why it matters — Royalty Pharma watchers would care because the article evaluates RPRX as a potentially more diversified alternative to investing directly in a single drug developer like Revolution Medicines.
Royalty Pharma plc (RPRX) presented at the Bank of America Global Healthcare Conference 2026, with a transcript of the presentation available via Seeking Alpha. The item reports on this conference participation.
Why it matters — A RPRX watcher would care because the conference presentation offers an opportunity to hear directly from company management about the business in a public forum.
The 8 Wall Street analysts covering Royalty Pharma plc have a median 12-month price target of $66, with estimates ranging from $61 to $70. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Royalty Pharma plc, 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Royalty Pharma plc 87 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Royalty Pharma plc ranks 87 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +17.4% from the last close, and Ticker Nerd's factor model ranks Royalty Pharma plc 87 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Royalty Pharma plc publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RPRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $61 to $70 over the next 12 months.
Royalty Pharma plc returned +59.2% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Royalty Pharma plc Class A Ordinary Shares represents an equity interest in Royalty Pharma plc, a New York-based biopharmaceutical royalty company. The company acquires and manages royalty interests tied to approved medicines and development-stage therapies, providing financing to drug developers and rights holders in exchange for a share of future product sales.
The most recent item we track (Zacks Investment Research, 8 Oct 2026): "Why Royalty Pharma (RPRX) is Poised to Beat Earnings Estimates Again". Zacks Investment Research says Royalty Pharma has an impressive history of earnings surprises and currently has two key ingredients associated with a likely beat in its next quarterly report.
Royalty Pharma plc Class A Ordinary Shares represents an equity interest in Royalty Pharma plc, a New York-based biopharmaceutical royalty company. The company acquires and manages royalty interests tied to approved medicines and development-stage therapies, providing financing to drug developers and rights holders in exchange for a share of future product sales. Its portfolio spans treatments in areas such as rare diseases, oncology, neuroscience, immunology, hematology, respiratory disease, infectious disease, and diabetes. Royalty Pharma also supports innovation by partnering with biotechnology and pharmaceutical companies, academic institutions, and research organizations across the life sciences sector. Through this model, the company serves as a specialized capital provider in the healthcare market, linking long-term funding needs with recurring revenue streams from commercialized therapies and pipeline assets.
CEO Mr. Pablo Legorreta · 100 employees · United States · https://www.royaltypharma.com
